title: Characteristics and factors associated with the clinical forms of lipoatrophy during highly active antiretroviral therapy in Ouagadougou, Burkina Faso.
abstract: BACKGROUND
  We aimed to study the factors associated with clinical forms of lipoatrophy in patients receiving highly active antiretroviral therapy (HAART) in Yalgado Ouédraogo Teaching Hospital, Ouagadougou, Burkina Faso.
  
  
  METHODS
  This cross-sectional review from March 10 to November 10, 2011, included a nonprobability sample of HIV-infected adults receiving antiretroviral (ARV) medications for at least 6 months and monitored in the internal medicine department. The diagnosis of lipoatrophy was clinical.
  
  
  RESULTS
  Three hundred patients were included. The sex ratio was 0.4 and the mean age was 42.1 ± 8.5 years. The mean duration of HAART was 73.2 ± 30.9 months. In all, 97 (32.3%) patients had lipoatrophy: 75 (25%) isolated and 22 (7.3%) mixed syndrome. Facial lipoatrophy was frequent (61.8%). Isolated lipoatrophy was associated with male sex (P = .002) and body mass index ≤25 (P < .05). Mixed syndrome was associated with female sex (P = .002), age >42 years (P < .05), physical activity (P = .003), smoking (P = .001), stavudine (d4T; P = .0001), or protease inhibitors (P = .01).
  
  
  CONCLUSIONS
  Prevention of lipoatrophy associated with HAART requires the exclusion of modifiable risk factors that we identified.
authors.affiliation: Unité de formation et de recherche en sciences de la santé, Université de Ouagadougou, Ouagadougou, Burkina Faso.
authors.forename: Oumar
authors.initials: O
authors.lastname: Guira
authors.forename: Hervé
authors.initials: H
authors.lastname: Tiéno
authors.forename: Bertille
authors.initials: B
authors.lastname: Yaméogo
authors.forename: Arnaud Eric
authors.initials: AE
authors.lastname: Diendéré
authors.forename: Nina
authors.initials: N
authors.lastname: Korsaga
authors.forename: Yempabou
authors.initials: Y
authors.lastname: Sagna
authors.forename: Lassané
authors.initials: L
authors.lastname: Zoungrana
authors.forename: Ismael
authors.initials: I
authors.lastname: Diallo
authors.forename: René
authors.initials: R
authors.lastname: Traoré
authors.forename: Joseph Youssouf
authors.initials: JY
authors.lastname: Drabo
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D015992:Body Mass Index; D002050:Burkina Faso / Q000453:epidemiology; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000453:epidemiology; D018119:Stavudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018119:Stavudine
keywords: Burkina Faso; HAART; lipoatrophy